Literature DB >> 33586036

The natural history of idiopathic pulmonary fibrosis in a large European population: the role of age, sex and comorbidities.

Antonella Caminati1, Fabiana Madotto2,3, Sara Conti3, Giancarlo Cesana3, Lorenzo Mantovani2,3, Sergio Harari4,5,6.   

Abstract

Placebo arms of clinical trials provide an opportunity to investigate the natural history of idiopathic pulmonary fibrosis (IPF) but these patients are not representative of the real life IPF population. Objective of this article is to evaluate patients' characteristics of incident IPF cases and their impact on mortality and hospitalizations risk. We conducted a retrospective cohort study using data from administrative databases from 2000 to 2010. Based on different algorithms reported in literature, incident IPF cases were identified. We applied Cox proportional hazards models to assess relationship between patients' characteristics, mortality and hospitalization. According to three case definitions, we identified 2338, 460 and 1704 incident IPF cases. Mean age at diagnosis was about 72 years, the proportion of male varied between 59 and 62% and patients with at least one chronic disease were between 70 and 74%. Age, male sex and comorbidities were associated to worse outcomes. Congestive heart failure (CHF), diabetes and cancer were conditions associated to mortality, while those associated to hospitalization were CHF and chronic obstructive pulmonary disease. Our data source provided one of the largest samples of unselected patients with a long follow-up period. Using different algorithms proposed and validated in literature, we observed that mortality and hospitalization rate are high in patients with IPF and age, sex and comorbidities significantly affect clinical outcomes. Females show a significant survival advantage over males, even after adjusting for age and comorbidities. Patients with pre-existing diseases, especially those with pulmonary and cardiovascular diseases are at higher risk.

Entities:  

Keywords:  Administrative databases; Epidemiology; Hospitalization; Mortality; Survival

Year:  2021        PMID: 33586036     DOI: 10.1007/s11739-021-02651-w

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  43 in total

Review 1.  Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium.

Authors:  Steven D Nathan; Oksana A Shlobin; Nargues Weir; Shahzad Ahmad; Julienne M Kaldjob; Edwinia Battle; Michael J Sheridan; Roland M du Bois
Journal:  Chest       Date:  2011-07       Impact factor: 9.410

2.  The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis.

Authors:  A G Nicholson; T V Colby; R M du Bois; D M Hansell; A U Wells
Journal:  Am J Respir Crit Care Med       Date:  2000-12       Impact factor: 21.405

3.  Clinical significance of histological classification of idiopathic interstitial pneumonia.

Authors:  K R Flaherty; G B Toews; W D Travis; T V Colby; E A Kazerooni; B H Gross; A Jain; R L Strawderman; R Paine; A Flint; J P Lynch; F J Martinez
Journal:  Eur Respir J       Date:  2002-02       Impact factor: 16.671

4.  Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis.

Authors:  J A Bjoraker; J H Ryu; M K Edwin; J L Myers; H D Tazelaar; D R Schroeder; K P Offord
Journal:  Am J Respir Crit Care Med       Date:  1998-01       Impact factor: 21.405

5.  BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Kevin K Brown; Ganesh Raghu; Roland M du Bois; David A Lynch; Fernando Martinez; Dominique Valeyre; Isabelle Leconte; Adele Morganti; Sébastien Roux; Juergen Behr
Journal:  Am J Respir Crit Care Med       Date:  2011-04-07       Impact factor: 21.405

6.  Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003.

Authors:  Amy L Olson; Jeffrey J Swigris; Dennis C Lezotte; Jill M Norris; Carla G Wilson; Kevin K Brown
Journal:  Am J Respir Crit Care Med       Date:  2007-05-03       Impact factor: 21.405

Review 7.  Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences.

Authors:  Sergio Harari; Antonella Caminati
Journal:  Eur Respir Rev       Date:  2015-09

8.  BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Jürgen Behr; Kevin K Brown; Roland M du Bois; Lisa Lancaster; Joao A de Andrade; Gerd Stähler; Isabelle Leconte; Sébastien Roux; Ganesh Raghu
Journal:  Am J Respir Crit Care Med       Date:  2007-09-27       Impact factor: 21.405

9.  Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study.

Authors:  Evans R Fernández Pérez; Craig E Daniels; Darrell R Schroeder; Jennifer St Sauver; Thomas E Hartman; Brian J Bartholmai; Eunhee S Yi; Jay H Ryu
Journal:  Chest       Date:  2009-09-11       Impact factor: 9.410

10.  Dynamic patient counseling: a novel concept in idiopathic pulmonary fibrosis.

Authors:  A Whitney Brown; Oksana A Shlobin; Nargues Weir; Maria C Albano; Shahzad Ahmad; Mary Smith; Kevin Leslie; Steven D Nathan
Journal:  Chest       Date:  2012-10       Impact factor: 9.410

View more
  4 in total

1.  Left-sided heart failure burden and mortality in idiopathic pulmonary fibrosis: a population-based study.

Authors:  Ardita Koteci; Ann D Morgan; Laura Portas; Hannah R Whittaker; Constantinos Kallis; Peter M George; Jennifer K Quint
Journal:  BMC Pulm Med       Date:  2022-05-12       Impact factor: 3.320

2.  Reticulation pattern without honeycombing on high-resolution CT is associated with the risk of disease progression in interstitial lung diseases.

Authors:  Minna Mononen; Eeva Saari; Hannele Hasala; Hannu-Pekka Kettunen; Sanna Suoranta; Hanna Nurmi; Miia Kärkkäinen; Tuomas Selander; Jukka Randell; Jari Laurikka; Toomas Uibu; Heikki Koskela; Riitta Kaarteenaho; Minna Purokivi
Journal:  BMC Pulm Med       Date:  2022-08-14       Impact factor: 3.320

Review 3.  Management of musculoskeletal pain in patients with idiopathic pulmonary fibrosis: a review.

Authors:  Svetlana Kašiković Lečić; Jovan Javorac; Dejan Živanović; Aleksandra Lovrenski; Dragana Tegeltija; Jelena Zvekić Svorcan; Jadranka Maksimović
Journal:  Ups J Med Sci       Date:  2022-07-11       Impact factor: 2.646

Review 4.  Harnessing the ECM Microenvironment to Ameliorate Mesenchymal Stromal Cell-Based Therapy in Chronic Lung Diseases.

Authors:  Linda Elowsson Rendin; Anna Löfdahl; Måns Kadefors; Zackarias Söderlund; Emil Tykesson; Sara Rolandsson Enes; Jenny Wigén; Gunilla Westergren-Thorsson
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.